NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.040
+0.040 (4.00%)
At close: Feb 13, 2026, 4:00 PM EST
0.9806
-0.0590 (-5.71%)
After-hours: Feb 13, 2026, 7:27 PM EST

NeuroSense Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-8.66-10.21-10.11-10.49-3.22-2.83
Depreciation & Amortization
0.020.020.020.0100
Loss (Gain) From Sale of Assets
----0.01-
Stock-Based Compensation
0.560.561.541.731.222.06
Other Operating Activities
-0.010.28-1.720.040.18-0
Change in Accounts Receivable
0.28-----0.01
Change in Accounts Payable
-0.39-0.30.960.46-0.020.03
Change in Other Net Operating Assets
-0.19-0.480.950.640.290.05
Operating Cash Flow
-8.39-10.14-8.35-7.62-1.54-0.7
Capital Expenditures
-0.01-0-0.03-0.07-0.02-0.01
Investment in Securities
003.5-3.52--
Other Investing Activities
-0.01-----
Investing Cash Flow
-0.0103.47-3.59-0.02-0.01
Issuance of Common Stock
8.2811.34.343.8711.90.51
Other Financing Activities
-0.38-0.39-0.36-0.1--
Financing Cash Flow
7.910.913.983.7711.90.51
Foreign Exchange Rate Adjustments
-0.04-0.040.01-0.090.02-
Net Cash Flow
-0.540.74-0.9-7.5210.36-0.2
Free Cash Flow
-8.39-10.14-8.38-7.69-1.56-0.7
Free Cash Flow Per Share
-0.37-0.55-0.61-0.67-0.25-0.13
Levered Free Cash Flow
-6.57-7.83-4.26-3.8-0.470.28
Unlevered Free Cash Flow
-6.57-7.83-4.26-3.8-0.470.28
Change in Working Capital
-0.3-0.781.911.10.270.07
Updated Aug 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q